Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Cartesian Therapeutics, Inc. (NASDAQ:RNAC), a biotechnology company with a market capitalization of $253 million, announced the appointment of June Seymour as chief accounting officer, effective upon the start of her full-time employment on October 27, 2025. The announcement comes as the company faces significant financial challenges, with InvestingPro data showing a 45% decline in stock value year-to-date. The announcement was made in a press release statement filed with the Securities and Exchange Commission.
Seymour, age 48, has more than 20 years of financial leadership experience in the life sciences sector. She most recently served as senior vice president of finance and accounting at DNAnexus, Inc. since May 2024. Prior to that, she was vice president of finance at Neogene Therapeutics Inc., where she oversaw financial operations during the company’s sale to AstraZeneca and subsequent post-acquisition integration from January 2022 to May 2024. Seymour also held finance roles at Autolus Ltd. from 2019 to 2022 and was a senior manager at Ernst & Young LLP in London from 2003 to 2019, specializing in U.S. transactions involving European life sciences companies. She holds a Bachelor of Science in Business Administration and Accountancy from Methodist University and is a Certified Public Accountant.
Under the terms of her employment agreement, Seymour will receive an annual base salary of $385,000 and will be eligible for an annual performance bonus targeted at 35% of her salary, prorated for the 2025 fiscal year. The agreement also provides for a sign-on bonus of $80,000 and an option to purchase 50,000 shares of Cartesian Therapeutics common stock at the closing price on her start date. The stock options will vest over four years, with 25% vesting after 12 months and the remainder vesting in three equal annual installments, subject to continued employment.
If Seymour’s employment is terminated without cause or she resigns for good reason, she will be entitled to six months of base salary, a prorated annual bonus, and up to six months of continued health coverage, provided she meets certain conditions. Seymour has also agreed to non-competition and non-solicitation covenants for up to 12 months following the end of her employment.
Blaine Davis, Cartesian’s chief financial officer, will continue to serve as the company’s principal financial officer and principal accounting officer.
In other recent news, Wedbush has initiated coverage on Cartesian Therapeutics with an Outperform rating. The firm set a price target of $38.00 for the company’s stock. Cartesian Therapeutics is noted by Wedbush for its development of mRNA cell therapies, which are highlighted as having significant advantages over traditional DNA-based CAR-T cell therapies. These developments reflect the company’s ongoing efforts in the field of immunology and inflammation. The Outperform rating suggests that Wedbush anticipates positive performance relative to the broader market. Investors may find these insights valuable as they assess Cartesian Therapeutics’ potential in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.